Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Net Income (2018 - 2025)

BioNexus Gene Lab's Net Income history spans 8 years, with the latest figure at -$708991.0 for Q3 2025.

  • For Q3 2025, Net Income rose 52.63% year-over-year to -$708991.0; the TTM value through Sep 2025 reached -$2.3 million, down 126.79%, while the annual FY2024 figure was -$1.6 million, 38.46% up from the prior year.
  • Net Income for Q3 2025 was -$708991.0 at BioNexus Gene Lab, down from -$616172.0 in the prior quarter.
  • Across five years, Net Income topped out at $351515.0 in Q4 2023 and bottomed at -$2.6 million in Q3 2023.
  • The 5-year median for Net Income is -$63621.0 (2024), against an average of -$300528.5.
  • The largest YoY upside for Net Income was 771.48% in 2023 against a maximum downside of 3271.0% in 2023.
  • A 5-year view of Net Income shows it stood at $115979.0 in 2021, then crashed by 145.14% to -$52349.0 in 2022, then soared by 771.48% to $351515.0 in 2023, then plummeted by 197.1% to -$341331.0 in 2024, then tumbled by 107.71% to -$708991.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Net Income are -$708991.0 (Q3 2025), -$616172.0 (Q2 2025), and -$623327.0 (Q1 2025).